衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法)
Multiplex Assay Kit for Fibulin 3 (FBLN3) ,etc. by FLIA (Flow Luminescence Immunoassay)
EFEMP1; DHRD; DRAD; FBNL; MLVT; MTLV; S1-5; EGF-Containing Fibulin-Like Extracellular Matrix Protein 1; Fibrillin-Like; Extracellular protein S1-5
(注:单次混测多因子不超过8个指标 )
- 编号LMF422Hu
- 物种Homo sapiens (Human,人) 相同的名称,不同的物种。
- 实验方法双抗夹心
- 反应时长3.5h
- 检测范围0.1-100ng/mL
- 灵敏度最小可检测剂量小于等于0.033 ng/mL.
- 样本类型Serum, plasma, urine and other biological fluids
- 下载 英文说明书 中文说明书
- 规格 8指标数 7指标数 6指标数 5指标数 4指标数 3指标数 2指标数1指标数
- 价格 ¥ 2621 ¥ 2722 ¥ 2873 ¥ 3074 ¥ 3276 ¥ 3578 ¥ 4032 计算器 ¥ 5040 添加到价格计算器
- 欲了解实际交易价格和更多情况,请与当地经销商联系!
特异性
本试剂盒用于检测衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法),经检测与其它相似物质无明显交叉反应。
由于受到技术及样本来源的限制,不可能完成对所有相关或相似物质交叉反应检测,因此本试剂盒有可能与未经检测的其它物质有交叉反应。
回收率
分别于定值血清及血浆样本中加入一定量的衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法)(加标样品),重复测定并计算其均值,回收率为测定值与理论值的比率。
样本 | 回收率范围(%) | 平均回收率(%) |
serum(n=5) | 97-105 | 101 |
EDTA plasma(n=5) | 90-98 | 94 |
heparin plasma(n=5) | 83-93 | 87 |
精密度
精密度用样品测定值的变异系数CV表示。CV(%) = SD/mean×100
批内差:取同批次试剂盒对低、中、高值定值样本进行定量检测,每份样本连续测定20 次,分别计算不同浓度样本的平均值及SD值。
批间差:选取3个不同批次的试剂盒分别对低、中、高值定值样本进行定量测定,每个样本使用同一试剂盒重复测定8次,分别计算不同浓度样本的平均值及SD值。
批内差: CV<10%
批间差: CV<12%
线性
在定值血清及血浆样本内加入适量的衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法),并倍比稀释成1:2,1:4,1:8,1:16的待测样本,线性范围即为稀释后样本中衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法)含量的测定值与理论值的比率。
样本 | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 92-103% | 78-97% | 85-104% | 87-101% |
EDTA plasma(n=5) | 86-93% | 93-104% | 80-91% | 92-105% |
heparin plasma(n=5) | 91-99% | 83-92% | 80-96% | 84-92% |
稳定性
经测定,试剂盒在有效期内按推荐温度保存,其活性降低率小于5%。
为减小外部因素对试剂盒破坏前后检测值的影响,实验室的环境条件需尽量保持一致,尤其是实验室内温度、湿度及温育条件。其次由同一实验员来进行操作可减少人为误差。
实验流程
1. 实验前标准品、试剂及样本准备;
2. 加样(标准品、样本、磁珠)标准品或样本100μL及磁珠10μL,
37°C酶标板振荡器孵育90分钟;
3. 磁吸甩干,加检测溶液A100μL,37°C酶标板振荡器孵育60分钟;
4. 磁吸洗板3次;
5. 加检测溶液B100μL,37°C振动孵育30分钟;
6. 磁吸洗板3次;
7. 加鞘液100μL,旋涡震荡2分钟后读数。
实验原理
将衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法)抗体包被于磁珠,制成固相载体,向微孔中分别加入标准品或标本以及磁珠,其中的衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法)与连接于固相载体上的抗体结合,然后加入生物素化的衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法)抗体,将未结合的生物素化抗体洗净后,加入PE标记的亲和素,再次彻底洗涤后即可上机读数。MFI值和样品中的衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法)呈正相关。
赠品
增值服务
相关产品
编号 | 适用物种:Homo sapiens (Human,人) | 应用(仅供研究使用,不用于临床诊断!) |
RPF422Hu02 | 衰老关键蛋白3(FBLN3)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPF422Hu01 | 衰老关键蛋白3(FBLN3)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAF422Hu01 | 衰老关键蛋白3(FBLN3)多克隆抗体 | WB; IHC; ICC; IP. |
PAF422Hu02 | 衰老关键蛋白3(FBLN3)多克隆抗体 | WB; IHC; ICC; IP. |
LAF422Hu71 | 衰老关键蛋白3(FBLN3)多克隆抗体(生物素标记) | WB; IHC; ICC. |
MAF422Hu23 | 衰老关键蛋白3(FBLN3)单克隆抗体 | WB; IHC; ICC; IP. |
MAF422Hu24 | 衰老关键蛋白3(FBLN3)单克隆抗体 | WB; IHC; ICC; IP. |
MAF422Hu22 | 衰老关键蛋白3(FBLN3)单克隆抗体 | WB |
MAF422Hu25 | 衰老关键蛋白3(FBLN3)单克隆抗体 | WB |
MAF422Hu21 | 衰老关键蛋白3(FBLN3)单克隆抗体 | WB |
SEF422Hu | 衰老关键蛋白3(FBLN3)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
SCF422Hu | 衰老关键蛋白3(FBLN3)检测试剂盒(化学发光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
LMF422Hu | 衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. |
参考文献
杂志 | 参考文献 |
1 | Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma [PubMed: PMC3761217] |
Anticancer Res. | YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis. [Pubmed: 24324091] |
Oncology Reports | Role of fibulin-3 in lung cancer: In vivo and in vitro analyses [Spandidos-publications: Source] |
Current Pulmonology Reports | Discovery of new biomarkers for malignant mesothelioma [Springer:Source] |
United States Patent Application 20140378336 | DIAGNOSIS OF CELL PROLIFERATIVE DISEASES [Freepatentsonline:Source] |
Thorax. | Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma [Pubmed:Pmc4174124] |
Egyptian Journal of Chest Diseases and Tuberculosis | Value of plasma and pleural effusion fibulin-3 levels in the diagnosis of malignant pleural mesothelioma effusions [Pubmed:23050525] |
Radiol Oncol | Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma [PubMed: 26401134] |
British Journal of Cancer | Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis [PubMed: 26263483] |
J Thorac Oncol. | Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma. [Pubmed:26903362] |
BMJ Open | Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study [pubmed:27884852] |
25 | HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients [pubmed:26733616] |
BMJ Journals | Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational … [e013324.abstract] |
Anticancer Res. | Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma. [pubmed:28314308] |
Dis Markers. | A Novel Panel of Serum Biomarkers for MPM Diagnosis. [pubmed:28348450] |
The Knee | Association of fibulin-3 concentrations with the presence and severity of knee osteoarthritis: A cross-sectional study [pubmed:29195846] |
Disease markers | Plasma Fibulin-3 as a Potential Biomarker for Patients with Asbestos-Related Diseases in the Han Population [pubmed:29200597] |
Molecular Medicine Reports | Placental protein 14 as a potential biomarker for diagnosis of preterm premature rupture of membranes [Pubmed:29749501] |
Oncotarget | The matrix protein Fibulin-3 promotes KISS1R induced triple negative breast cancer cell invasion [Pubmed:30046386] |
Advances in Clinical and Experimental Medicine | Fibulin-3 and other cartilage metabolism biomarkers in relationship to calprotectin (MRP8/14) and disease activity in rheumatoid arthritis patients treated with … [68362.pdf] |
PLoS One | Prediction of pneumoconiosis by serum and urinary biomarkers in workers exposed to asbestos-contaminated minerals [Pubmed: 30946771] |